Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueDepreciation & Amortization (IS)Depreciation ExpenseEBIATGross ProfitLeasesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetShares IssuedShares OutstandingShares Outstanding
Ratios

Amicus Therapeutics (FOLD) Cost of Revenue (2016 - 2025)

Amicus Therapeutics filings provide 10 years of Cost of Revenue readings, the most recent being $26.5 million for Q4 2025.

  • On a quarterly basis, Cost of Revenue rose 78.94% to $26.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $72.9 million, a 37.75% increase, with the full-year FY2025 number at $72.9 million, up 37.75% from a year prior.
  • Cost of Revenue hit $26.5 million in Q4 2025 for Amicus Therapeutics, up from $19.5 million in the prior quarter.
  • In the past five years, Cost of Revenue ranged from a high of $26.5 million in Q4 2025 to a low of $6.5 million in Q1 2021.
  • Median Cost of Revenue over the past 5 years was $11.3 million (2023), compared with a mean of $11.8 million.
  • Biggest five-year swings in Cost of Revenue: fell 25.97% in 2023 and later skyrocketed 95.43% in 2024.
  • Amicus Therapeutics' Cost of Revenue stood at $7.9 million in 2021, then rose by 19.53% to $9.4 million in 2022, then grew by 20.67% to $11.3 million in 2023, then soared by 31.01% to $14.8 million in 2024, then skyrocketed by 78.94% to $26.5 million in 2025.
  • The last three reported values for Cost of Revenue were $26.5 million (Q4 2025), $19.5 million (Q3 2025), and $15.2 million (Q2 2025) per Business Quant data.